Literature DB >> 3006713

Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.

F Makovec, M Bani, R Chisté, L Revel, L C Rovati, L A Rovati.   

Abstract

Three glutaramic acid derivatives provided with a potent antagonistic activity on the contractions elicited by the carboxyl terminal octapeptide CCK-8 in the guinea pig gallbladder have been evaluated for their capacity to inhibit the binding of [125I]-(Bolton-Hunter)-CCK-8 to both central and peripheric cholecystokinin (CCK) receptors. The most active compound inhibits the CCK binding to rat pancreas acini at a concentration 10(-7) mol/l, but only at 10(-4) mol/l on cerebral cortex membranes, confirming the existence of at least two different populations of CCK receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006713

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

Authors:  P Hildebrand; C Beglinger; K Gyr; J B Jansen; L C Rovati; M Zuercher; C B Lamers; I Setnikar; G A Stalder
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 2.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

3.  Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.

Authors:  M Otsuki; M Fujii; T Nakamura; Y Okabayashi; S Tani; T Fujisawa; M Koide; S Baba
Journal:  Dig Dis Sci       Date:  1989-06       Impact factor: 3.199

4.  Cholecystokinin-induced regulation of muscarinic receptor on dispersed pancreatic acini.

Authors:  E Aoki; H Adachi; M Noguchi; T Honda; S Sato; S Onishi; S Katsushima; J Konishi
Journal:  Gastroenterol Jpn       Date:  1990-10

5.  CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.

Authors:  X J Xu; Z Wiesenfeld-Hallin; J Hughes; D C Horwell; T Hökfelt
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

6.  Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder.

Authors:  M A Maselli; A L Piepoli; F Pezzolla; V Guerra; M L Caruso; L Mennuni; D Lorusso; F Makovec
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 7.  Perspectives of CCK antagonists in pancreatic research. Part II. Experimental studies.

Authors:  T Takács; A Pap
Journal:  Int J Pancreatol       Date:  1991-09

8.  Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestine.

Authors:  L Barthó; P Holzer; F Lembeck; I T Lippe; I Setnikar
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

9.  CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.

Authors:  J W Konturek; S J Konturek; A Kurek; J Bogdal; J Oleksy; L Rovati
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

Review 10.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.